Evidence map›Paper›PMID 37569299›Full record

ReviewInternational journal of molecular sciences2023

Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer.

Ronald Anderson, Bernardo L Rapoport, Helen C Steel, Annette J Theron

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ronald AndersonDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa.ORCID 0000-0002-5925-6452
Bernardo L RapoportDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa.ORCID 0000-0001-7610-3653
Helen C SteelDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa.ORCID 0000-0001-5899-4472
Annette J TheronDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa.ORCID 0000-0002-7359-5952
University of Pretoria · ZAThe Medical Oncology Centre of Rosebank · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aside from their key protective roles in hemostasis and innate immunity, platelets are now recognized as having multifaceted, adverse roles in the pathogenesis, progression and outcome of many types of human malignancy. The most consistent and compelling evidence in this context has been derived from the notable association of elevated circulating platelet counts with the onset and prognosis of various human malignancies, particularly lung cancer, which represents the primary focus of the current review. Key topics include an overview of the association of lung cancer with the circulating platelet count, as well as the mechanisms of platelet-mediated, pro-tumorigenic immunosuppression, particularly the role of transforming growth factor beta 1. These issues are followed by a discussion regarding the pro-tumorigenic role of platelet-derived microparticles (PMPs), the most abundant type of microparticles (MPs) in human blood. In this context, the presence of increased levels of PMPs in the blood of lung cancer patients has been associated with tumor growth, invasion, angiogenesis and metastasis, which correlate with disease progression and decreased survival times. The final section of the review addresses, firstly, the role of cancer-related platelet activation and thrombosis in the pathogenesis of secondary cardiovascular disorders and the associated mortality, particularly in lung cancer, which is second only to disease progression; secondly, the review addresses the potential role of antiplatelet agents in the adjunctive therapy of cancer.

Indexed as

Cell-Derived MicroparticlesLung NeoplasmsThrombosisBlood PlateletsCarcinogenesisDisease ProgressionHumansimmunosuppressionlung cancerlung-cancer-associated thrombosisplatelet-derived vesiclesplatelet factor 4plateletstissue factortransforming growth factor beta 1

Identifiers

PMID37569299
PMCPMC10418868
OpenAlexW4385278676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.